Free tool
FAERS Monitor: Wezlana
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761285 or its brand name (Wezlana, Ustekinumab-Auub). Reports on generic versions are filed under their own applications.
Reports
175
Serious
153
87% of reports
Hospitalization
35
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- crohn^s disease27
- off label use25
- colitis ulcerative21
- inappropriate schedule of product administration19
- drug ineffective15
- diarrhoea14
- psoriasis10
- fatigue9
- death8
- haematochezia7
- headache7
- frequent bowel movements6
- nausea6
- therapy interrupted6
- abdominal pain5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 6 |
| 2025 | 49 |
| 2026 | 120 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,984 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colitis ulcerativeSignal | 21 | 56.5 | 37.8 | 1,092 |
| frequent bowel movementsSignal | 6 | 26.7 | 12.2 | 124 |
| haematocheziaSignal | 7 | 15.2 | 7.4 | 80 |
| inappropriate schedule of product administrationSignal | 19 | 12.7 | 8.3 | 194 |
| therapy interruptedSignal | 6 | 10.1 | 4.6 | 41 |
| psoriasisSignal | 10 | 9.2 | 5.0 | 66 |
| off label useSignal | 25 | 3.4 | 2.4 | 42 |
| diarrhoeaSignal | 14 | 2.6 | 1.6 | 13 |
| abdominal pain | 5 | 2.6 | 1.1 | 3 |
| fatigue | 9 | 1.4 | 0.7 | 1 |
| drug ineffective | 15 | 1.4 | 0.8 | 1 |
| headache | 7 | 1.3 | 0.6 | 0 |
| death | 8 | 1.1 | 0.6 | 0 |
| nausea | 6 | 0.9 | 0.4 | 0 |
| crohn^s disease | 27 | 0.0 | 0.0 | 3,129,137 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.